Compare Vanguard Intermediate Term Corporate Bond ETF (VCIT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Intermediate Term Corporate Bond ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Vanguard Intermediate Term Corporate Bond ETF trades at $81.54, while Vertex Pharmaceuticals Incorporated trades at $478.06 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| VCIT | VRTX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $84.82 | $529.59 |
52-Week Low | $81.45 | $366.54 |
Market Cap | — | $121.95B |
Enterprise Value | — | $116.69B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
